Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Par Pharmaceutical Companies, a US-based specialty pharmaceutical company, has entered into a settlement agreement with Sanofi-aventis to resolve patent dispute related to generic version of colorectal cancer treatment Eloxatin.
Subscribe to our email newsletter
Eloxatin, combined with the chemotherapy regimen of 5-FU/LV, is approved by the FDA for the treatment of advanced colorectal cancer (cancer of the colon and/or rectum).
Sanofi, under licensing agreement with Switzerland-based Debiopharm, markets Eloxatin. Sanofi has filed lawsuit against Par, along with other makers of generic versions of Eloxatin, in 2007 for patent infringement.
Under the settlement, Par is expected to begin selling its generic version of Eloxatin in August 2012, or earlier under certain circumstances.
The settlement agreements are subject to review by the Federal Trade Commission, the US Department of Justice, and the Attorney General for the State of Michigan.